<bill session="118" type="s" number="526" updated="2025-11-19T02:31:25Z">
  <state datetime="2023-02-16">REFERRED</state>
  <status>
    <introduced datetime="2023-02-16"/>
  </status>
  <introduced datetime="2023-02-16"/>
  <titles>
    <title type="display">BENEFIT Act of 2023</title>
    <title type="short" as="introduced">BENEFIT Act of 2023</title>
    <title type="short" as="introduced">Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023</title>
    <title type="official" as="introduced">A bill to strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.</title>
  </titles>
  <sponsor bioguide_id="W000437"/>
  <cosponsors>
    <cosponsor bioguide_id="B001310" joined="2023-03-28"/>
    <cosponsor bioguide_id="C001035" joined="2023-03-08"/>
    <cosponsor bioguide_id="H000601" joined="2024-04-30"/>
    <cosponsor bioguide_id="K000367" joined="2023-02-16"/>
    <cosponsor bioguide_id="S001217" joined="2023-10-17"/>
  </cosponsors>
  <actions>
    <action datetime="2023-02-16">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2023-02-16" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referred To"/>
  </committees>
  <relatedbills>
    <bill session="118" type="h" number="1092" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2023-06-21T21:27:01Z" status="Introduced in Senate">Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023 or the BENEFIT Act of 2023

This bill requires the Food and Drug Administration (FDA) to consider relevant patient experience data in the risk-benefit assessment framework used in the process for approving new drugs.

After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.</summary>
</bill>
